Trending Now
Software & Data
AstraZeneca Launches Evinova, A Company Offering Digital Solutions for Clinical Trials
AstraZeneca has unveiled a new standalone company, Evinova, aimed at providing contract research organizations (CROs) and pharmaceutical companies with access to its established digital solutions for conducting clinical trials. With a team of 300 members drawn from AstraZeneca and spanning nine countries, Evinova will offer a "drug development suite" based on proven trial solutions employed across AstraZeneca's disease areas...
Medical Devices
Finally: Medtronic’s Symplicity Spyral Renal Denervation System Secures FDA Approval After...
Medtronic has achieved FDA approval for its Symplicity Spyral renal denervation (RDN) system, marking a pivotal moment after a decade of pursuit. The device targets uncontrolled high blood pressure and is set for near-term commercialization...
Consumer Internet
Masimo Receives FDA Clearance for Groundbreaking Wearable
Masimo, a global leader in non-invasive monitoring technologies, has achieved a significant milestone with the FDA granting 510(k) clearance for its groundbreaking medical watch, the Masimo W1. This clearance allows both over-the-counter and prescription use of the watch, marking a major advancement in continuous monitoring capabilities for real-time oxygen saturation (SpO2) and pulse rate...
Biotech
Merck Expands Presence in Neurodegenerative Research with Caraway Therapeutics Acquisition
In a strategic move to bolster its research presence in neurodegenerative diseases, Merck & Co. has announced its acquisition of private biotechnology company Caraway Therapeutics. The deal, valued at up to $610 million, includes an undisclosed upfront payment along with conditional milestone payments...
Features
Taldefgrobep Alfa by Biohaven Could Change The Weight-Loss Drug Landscape
Biohaven, a Connecticut-based biopharmaceutical company, is exploring a potential game-changer in the weight-loss drug landscape with its investigational drug, taldefgrobep alfa. In a market dominated by blockbuster drugs like Ozempic and Wegovy, which belong to the glucagon-like peptide-1 (GLP-1) agonist class, Biohaven aims to address concerns about the quality of weight loss generated by existing medications...